Anti-obesity effect of intranasal administration of galanin-like peptide (GALP) in obese mice.
Galanin-like peptide (GALP) has an anti-obesity effect in rats and mice. It has been reported that the uptake of GALP by the brain is higher after intranasal administration than with intravenous injection. This study therefore aimed to clarify the effect of intranasal administration of GALP on the feeding behavior of lean and obese mice. Autoradiography revealed the presence of (125)I-GALP in the olfactory bulb and the brain microcirculation. The body weights of ob/ob mice gradually increased during vehicle treatment, but remained unchanged in response to repeated intranasal administration of GALP, with both ob/ob and diet-induced obese mice displaying significantly decreased food intake, water intake and locomotor activity when treated with GALP. These results suggest that intranasal administration is an effective route whereby GALP can exert its effect as an anti-obesity drug.
Division of Nutrition, Faculty of Health Care, Kiryu University, Gunma 379-2392, Japan.
Haruaki
H
Kageyama
Department of Anatomy, Showa University School of Medicine, Tokyo, 142-8555, Japan.
Kanako
K
Shiba
Department of Health and Nutrition, University of Human Arts and Sciences, Saitama 339-8539, Japan.
Satoshi
S
Hirako
Department of Anatomy, Showa University School of Medicine, Tokyo, 142-8555, Japan.|Department of Internal Medicine, Graduate school of Medicine, University of Tokyo, Tokyo 113-8655, Japan.
Nobuhiro
N
Wada
Department of Anatomy, Showa University School of Medicine, Tokyo, 142-8555, Japan.
Satoru
S
Yamanaka
Department of Medicine, Division of Diabetes, Metabolism, and Endocrinology, Showa University School of Medicine, Tokyo 142-8555, Japan.
Yukinori
Y
Nogi
Department of Exercise and Sports Physiology, Hoshi University School of Pharmacy and Pharmaceutical Science, Tokyo 142-8501, Japan.
Fumiko
F
Takenoya
Department of Oral Anatomy and Developmental Biology, School of Dentistry, Showa University, Tokyo 142-8555, Japan.
Naoko
N
Nonaka
Department of Medicine, Division of Diabetes, Metabolism, and Endocrinology, Showa University School of Medicine, Tokyo 142-8555, Japan.
Tsutomu
T
Hirano
Division of Nutrition, Faculty of Health Care, Kiryu University, Gunma 379-2392, Japan.
Shuji
S
Inoue
Hoshi University School of Pharmacy and Pharmaceutical Sciences, Global Research Center for Innovative Life Science, Peptide Drug Innovation, Tokyo 142-8501, Japan.
Seiji
S
Shioda
D000281:Administration, Intranasal; D000818:Animals; D019440:Anti-Obesity Agents / Q000627:therapeutic use*; D001345:Autoradiography; D001835:Body Weight; D001921:Brain / Q000473:pathology*; D004734:Energy Metabolism; D044089:Galanin-Like Peptide / Q000627:therapeutic use*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008820:Mice, Obese; D009765:Obesity / Q000188:drug therapy*; D051381:Rats; D017207:Rats, Sprague-Dawley
D019440:Anti-Obesity Agents; D044089:Galanin-Like Peptide